Results 101 to 110 of about 61,341 (287)

[Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)].

Kardiologiia, 2020
Introduction The aim of this study was to assess the efficacy and safety of a combination of bromhexine at a dose of 8 mg 4 times a day and spironolactone 50 mg per day in patients with mild and moderate COVID 19.Material and methods It was an open ...
V. Mareev, Y. Orlova, A. G. Plisyk, E. Pavlikova, S. Matskeplishvili, Z. Akopyan, E. Seredenina, A. Potapenko, M. Agapov, D. A. Asratyan, L. I. Dyachuk, L. Samokhodskaya, Е. А. Mershina, V. Sinitsyn, P. V. Pakhomov, M. M. Bulanova, A. A. Fuks, Y. Mareev, Y. Begrambekova, А. Kamalov   +19 more
semanticscholar   +1 more source

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials [PDF]

, 2023
Karl‐Patrik Kresoja, Matthias Unterhuber, Rolf Wachter, Karl‐Philipp Rommel, Christian Besler, Sanjiv J. Shah, Hölger Thiele, Frank Edelmann, Philipp Lurz   +8 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction

ESC Heart Failure, 2020
Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan, Shouji Matsushima, Tomomi Ide, Hidetaka Kaku, Taiki Higo, Miyuki Tsuchihashi‐Makaya, Hiroyuki Tsutsui   +6 more
doaj   +1 more source

Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. [PDF]

, 2003
The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone ...
Kirim, Sinan, Sert, Murat, Tetiker, Tamer   +2 more
core   +1 more source

Furosemide and spironolactone doses and hyponatremia in patients with heart failure

BMC Pharmacology and Toxicology, 2020
Background Hyponatremia, a marker of disease severity and prognosis, has been associated with various clinical factors and drug use, especially diuretics.
Ivan Velat, Ž. Bušić, Marina Jurić Paić, V. Čulić   +3 more
semanticscholar   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Protective Effect of Spironolactone on Endothelial-to-Mesenchymal Transition in HUVECs via Notch Pathway

Cellular Physiology and Biochemistry, 2015
Background: Fibrosis results in excessive buildup of extracellular matrix proteins along with abnormalities in structure and is partly derived by a process involving transforming growth factor β (TGF-β) called endothelial-to-mesenchymal transition (EndMT)
Xiao Chen, Jiejie Cai, Xi Zhou, Lingzhi Chen, Yongsheng Gong, Zhan Gao, Huaiqin Zhang, Weijian Huang, Hao Zhou   +8 more
doaj   +1 more source

Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

BMC Nephrology, 2020
Background Limited evidence has indicated that addition of a steroidal mineralocorticoid receptor antagonist (MRA) to the standard of care reduces proteinuria in patients with diabetic kidney disease (DKD); however, there are limited data regarding real ...
Michael Blankenburg, Csaba P. Kovesdy, Anne-Kathrin Fett, Raymond G. Griner, Alain Gay   +4 more
doaj   +1 more source

Spironolactone and colitis: Increased mortality in rodents and in humans [PDF]

, 2012
Background: Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context
Akbar K. Waljee, Andres, Brenda W. Gillespie, Carter, Charlson, Chun, Deyo, Ersoy, Fan, Gullulu, Higgins, Huang, Ibrahim, Jarvis, Joel C. Joyce, Kamath, Kim, Kuehne, Kyne, Laura A. Johnson, Livak, Louis, Lyerly, Lyras, Mezzano, Nishimura, Ochs, Overdiek, Patel, Peter D.R. Higgins, Pitt, Powell, Rajagopalan, Sands, Semler, Shail M. Govani, Sungaila, Thannickal, Tian, Tox, Witteck   +40 more
core   +1 more source